These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 35997804)

  • 1. Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia.
    Luna A; Pérez-Lamas L; Boque C; Giraldo P; Xicoy B; Ruiz Nuño C; Vega MM; Alvarez-Larrán A; Salamanca A; García-Noblejas A; Vall-Llovera F; Villalon L; De Las Heras N; Ramila E; Pérez-Encinas M; Cuevas B; Perez-Lopez R; Sanchez-Guijo F; Jiménez-Velasco A; Lakhwani S; Casado LF; Rosell A; Escola A; Fernández MJ; Garcia-Hernandez C; Cervero C; Mora E; Sagüés M; Suarez-Varela S; Vélez P; Carrascosa Mastell P; Bitaube RF; Serrano L; Cortes M; Vera Goñi JA; Steegmann JL; de Soria VGG; Alonso-Dominguez JM; Araujo MC; Coll AP; Hernandez-Boluda JC; García-Gutiérrez V
    Ann Hematol; 2022 Oct; 101(10):2263-2270. PubMed ID: 35997804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.
    Hughes TP; Mauro MJ; Cortes JE; Minami H; Rea D; DeAngelo DJ; Breccia M; Goh YT; Talpaz M; Hochhaus A; le Coutre P; Ottmann O; Heinrich MC; Steegmann JL; Deininger MWN; Janssen JJWM; Mahon FX; Minami Y; Yeung D; Ross DM; Tallman MS; Park JH; Druker BJ; Hynds D; Duan Y; Meille C; Hourcade-Potelleret F; Vanasse KG; Lang F; Kim DW
    N Engl J Med; 2019 Dec; 381(24):2315-2326. PubMed ID: 31826340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ponatinib for the treatment of adult patients with resistant or intolerant Chronic-Phase Chronic Myeloid Leukemia.
    Haddad FG; Issa GC; Jabbour E; Yilmaz M
    Expert Opin Pharmacother; 2022 May; 23(7):751-758. PubMed ID: 35412404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results.
    Cortes JE; Sasaki K; Kim DW; Hughes TP; Etienne G; Mauro MJ; Hochhaus A; Lang F; Heinrich MC; Breccia M; Deininger M; Goh YT; Janssen JJWM; Talpaz M; de Soria VGG; le Coutre P; DeAngelo DJ; Damon A; Cacciatore S; Polydoros F; Agrawal N; Rea D
    Leukemia; 2024 Jul; 38(7):1522-1533. PubMed ID: 38755421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Asciminib (Scemblix): A third-line treatment option for chronic myeloid leukemia in chronic phase with or without T315I mutation.
    Monestime S; Al Sagheer T; Tadros M
    Am J Health Syst Pharm; 2023 Jan; 80(2):36-43. PubMed ID: 36197958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.
    Eide CA; Zabriskie MS; Savage Stevens SL; Antelope O; Vellore NA; Than H; Schultz AR; Clair P; Bowler AD; Pomicter AD; Yan D; Senina AV; Qiang W; Kelley TW; Szankasi P; Heinrich MC; Tyner JW; Rea D; Cayuela JM; Kim DW; Tognon CE; O'Hare T; Druker BJ; Deininger MW
    Cancer Cell; 2019 Oct; 36(4):431-443.e5. PubMed ID: 31543464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes of chronic myeloid leukaemia patients taking asciminib through a Managed Access Programme (MAP) in Australia.
    Chee L; Lee N; Grigg A; Chen M; Schwarer A; Szer J; Ratnasingam S; Raj S; Lukito P; Yeung D; Hughes T; Shanmuganathan N
    Intern Med J; 2024 Jul; 54(7):1214-1218. PubMed ID: 38884158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacological and clinical profile of asciminib hydrochloride, a novel first-in-class tyrosine kinase inhibitor specifically targeting ABL myristoyl pocket].
    Chung J; Ariyoshi T; Yoneda T; Kagawa Y; Kawakita Y; Maki A
    Nihon Yakurigaku Zasshi; 2023; 158(3):273-281. PubMed ID: 37121712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An evaluation of asciminib for patients with chronic myeloid leukemia previously treated with ≥2 tyrosine kinase inhibitors.
    García-Gutiérrez V; Hernandez-Boluda JC
    Expert Rev Hematol; 2022 Jun; 15(6):477-484. PubMed ID: 35583386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Asciminib for third-line treatment of chronic myeloid leukemia: Cost-effectiveness analysis based on treatment-free remission approach.
    García Molina A
    Farm Hosp; 2024; 48(5):T222-T229. PubMed ID: 39013681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Asciminib for third-line treatment of chronic myeloid leukemia: Cost-effectiveness analysis based on treatment-free remission approach.
    Garcia Molina A
    Farm Hosp; 2024; 48(5):222-229. PubMed ID: 38679535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asciminib: a new therapeutic option in chronic-phase CML with treatment failure.
    Yeung DT; Shanmuganathan N; Hughes TP
    Blood; 2022 Jun; 139(24):3474-3479. PubMed ID: 35468180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Shamroe CL; Comeau JM
    Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of Chronic Myeloid Leukemia Patients in Later Lines: The Role of Ponatinib and New Compounds.
    Scalzulli E; Carmosino I; Costa A; Bisegna ML; Martelli M; Breccia M
    Clin Lymphoma Myeloma Leuk; 2023 Jun; 23(6):420-425. PubMed ID: 37029061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Follow-Up in Patients With Chronic Myeloid Leukemia Treated With Ponatinib in a Real-World Cohort: Safety and Efficacy Analysis.
    Mela Osorio MJ; Moiraghi B; Osycka MV; Pavlovsky MA; Varela AI; Bendek Del Prete GE; Tosin MF; Pérez MA; Riva ME; Berrios RR; Fernández I; Sackmann Massa F; Giere I; Sighel C; Pavlovsky C
    Clin Lymphoma Myeloma Leuk; 2024 Mar; 24(3):158-164. PubMed ID: 37973457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High Efficacy and Safety of Asciminib in a Chronic Myeloid Leukemia Patient with Chronic Kidney Disease Following Renal Transplantation.
    Uchida Y; Koyama D; Manabe K; Suzuki K; Asano N; Endo M; Fukatsu M; Sano T; Hayashi K; Takano M; Takahashi H; Kimura S; Ikezoe T
    Intern Med; 2024 Mar; 63(5):717-720. PubMed ID: 37407456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ponatinib in refractory Philadelphia chromosome-positive leukemias.
    Cortes JE; Kantarjian H; Shah NP; Bixby D; Mauro MJ; Flinn I; O'Hare T; Hu S; Narasimhan NI; Rivera VM; Clackson T; Turner CD; Haluska FG; Druker BJ; Deininger MW; Talpaz M
    N Engl J Med; 2012 Nov; 367(22):2075-88. PubMed ID: 23190221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overcoming clinical BCR-ABL1 compound mutant resistance with combined ponatinib and asciminib therapy.
    Eide CA; Brewer D; Xie T; Schultz AR; Savage SL; Muratcioglu S; Merz N; Press RD; O'Hare T; Jacob T; Vu TQ; Tognon CE; Macey TA; Kuriyan J; Kalodimos CG; Druker BJ
    Cancer Cell; 2024 Sep; 42(9):1486-1488. PubMed ID: 39214096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Asciminib in Newly Diagnosed Chronic Myeloid Leukemia.
    Hochhaus A; Wang J; Kim DW; Kim DDH; Mayer J; Goh YT; le Coutre P; Takahashi N; Kim I; Etienne G; Andorsky D; Issa GC; Larson RA; Bombaci F; Kapoor S; McCulloch T; Malek K; Yau L; Ifrah S; Hoch M; Cortes JE; Hughes TP;
    N Engl J Med; 2024 Sep; 391(10):885-898. PubMed ID: 38820078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigating Potential Cardiovascular Toxicity of Two Anti-Leukemia Drugs of Asciminib and Ponatinib in Zebrafish Embryos.
    Lin HC; Saputra F; Audira G; Lai YH; Roldan MJM; Alos HC; Aventurado CA; Vasquez RD; Tsai GJ; Lim KH; Hsiao CD
    Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.